S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
The "King Of Quants" sees 10X potential... (Ad)
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
The "King Of Quants" sees 10X potential... (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
The "King Of Quants" sees 10X potential... (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
The "King Of Quants" sees 10X potential... (Ad)
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
The "King Of Quants" sees 10X potential... (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
The "King Of Quants" sees 10X potential... (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
The "King Of Quants" sees 10X potential... (Ad)
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
The "King Of Quants" sees 10X potential... (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
The "King Of Quants" sees 10X potential... (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
5 Best Dividend Capture Stocks
The "King Of Quants" sees 10X potential... (Ad)
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Closing prices for crude oil, gold and other commodities
The "King Of Quants" sees 10X potential... (Ad)
Dividend King Genuine Parts Company Upgraded On Profit Guidance
11 Best Consumer Discretionary Stocks of 2023
The "King Of Quants" sees 10X potential... (Ad)
The Bottom Is In For Accenture
14 Best Consumer Staples Dividend Stocks
NASDAQ:GLPG

Galapagos - GLPG Competitors

$37.55
-0.09 (-0.24%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$37.04
$37.64
50-Day Range
$36.67
$48.00
52-Week Range
$36.20
$72.11
Volume
144,123 shs
Average Volume
278,064 shs
Market Capitalization
$2.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.17

GLPG vs. PRTA, SAGE, HRMY, HCM, ARWR, BPMC, RARE, MYOV, MRTX, and RVNC

Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Prothena (PRTA), Sage Therapeutics (SAGE), Harmony Biosciences (HRMY), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Myovant Sciences (MYOV), Mirati Therapeutics (MRTX), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.

Galapagos vs.

Galapagos (NASDAQ:GLPG) and Prothena (NASDAQ:PRTA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking.

In the previous week, Prothena had 3 more articles in the media than Galapagos. MarketBeat recorded 5 mentions for Prothena and 2 mentions for Galapagos. Galapagos' average media sentiment score of 0.02 beat Prothena's score of -0.16 indicating that Galapagos is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galapagos
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prothena
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

19.5% of Galapagos shares are held by institutional investors. Comparatively, 91.7% of Prothena shares are held by institutional investors. 2.9% of Galapagos shares are held by company insiders. Comparatively, 31.2% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Galapagos has a net margin of -42.15% compared to Prothena's net margin of -216.95%. Galapagos' return on equity of -5.08% beat Prothena's return on equity.

Company Net Margins Return on Equity Return on Assets
Galapagos -42.15% -5.08% -2.68%
Prothena -216.95% -24.98% -19.15%

Prothena received 123 more outperform votes than Galapagos when rated by MarketBeat users. Likewise, 71.50% of users gave Prothena an outperform vote while only 66.14% of users gave Galapagos an outperform vote.

CompanyUnderperformOutperform
GalapagosOutperform Votes
459
66.14%
Underperform Votes
235
33.86%
ProthenaOutperform Votes
582
71.50%
Underperform Votes
232
28.50%

Prothena has lower revenue, but higher earnings than Galapagos. Prothena is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$532.48 million4.64-$229.73 million-$3.43-10.95
Prothena$53.90 million45.90-$116.95 million-$2.51-18.75

Galapagos currently has a consensus target price of $49.17, suggesting a potential upside of 30.95%. Prothena has a consensus target price of $82.50, suggesting a potential upside of 75.27%. Given Prothena's stronger consensus rating and higher possible upside, analysts plainly believe Prothena is more favorable than Galapagos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galapagos
0 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Prothena
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88

Galapagos has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Summary

Prothena beats Galapagos on 12 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLPG vs. The Competition

MetricGalapagosPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.47B$5.53B$4.34B$5.89B
Dividend YieldN/A2.59%2.39%4.41%
P/E Ratio-10.959.80153.2415.53
Price / Sales4.64316.603,472.7260.89
Price / CashN/A19.7427.45103.34
Price / Book0.794.184.474.95
Net Income-$229.73M$186.46M$115.09M$190.72M
7 Day Performance-3.67%-1.13%-0.82%0.70%
1 Month Performance-1.68%-8.33%-6.59%-6.02%
1 Year Performance-39.60%-13.96%-16.04%-18.22%

Galapagos Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRTA
Prothena
1.8976 of 5 stars
$46.97
-4.4%
$82.50
+75.6%
+24.4%$2.47B$53.90M-18.7182Insider Selling
SAGE
Sage Therapeutics
2.1787 of 5 stars
$42.03
-2.9%
$51.14
+21.7%
+27.6%$2.51B$7.69M-4.68471Positive News
HRMY
Harmony Biosciences
2.5402 of 5 stars
$42.23
-4.0%
$61.89
+46.6%
-16.9%$2.52B$437.86M14.22180Positive News
HCM
HUTCHMED
1.3173 of 5 stars
$14.59
-2.7%
$16.00
+9.7%
-33.7%$2.52B$426.41M0.002,025
ARWR
Arrowhead Pharmaceuticals
2.3852 of 5 stars
$23.72
-3.6%
$57.09
+140.7%
-48.4%$2.57B$278.34M-16.14329Analyst Report
News Coverage
BPMC
Blueprint Medicines
2.108 of 5 stars
$43.52
-4.4%
$73.53
+68.9%
-34.2%$2.61B$204.04M-4.65495Analyst Report
RARE
Ultragenyx Pharmaceutical
2.789 of 5 stars
$37.28
-2.8%
$88.67
+137.8%
-45.5%$2.62B$363.33M-3.691,311
MYOV
Myovant Sciences
1.1107 of 5 stars
$26.98
0.0%
$21.33
-20.9%
+87.8%$2.62B$230.97M-14.13407
MRTX
Mirati Therapeutics
2.0238 of 5 stars
$39.54
-2.9%
$80.87
+104.5%
-52.4%$2.29B$12.44M-3.00413
RVNC
Revance Therapeutics
2.448 of 5 stars
$31.78
-3.1%
$40.91
+28.7%
+59.1%$2.63B$132.57M-6.61495
This page (NASDAQ:GLPG) was last updated on 3/25/2023 by MarketBeat.com Staff